Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 13/20 | 0.54 |
| ▸ | NOS1 | P29475 | 2/20 | 0.54 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3563614 | 0.92 | NOS2 (0.51) | NOS2NOS1HTR1DCYP1A2CYP3A4 | |
| SCHEMBL3559827 | 0.85 | NOS2 (0.44) | NOS2NOS1PDE5A | |
| SCHEMBL3571989 | 0.81 | NOS2 (0.53) | NOS2NOS1TSHRMAPK1NPC1 | |
| SCHEMBL3569171 | 0.74 | NOS2 (0.41) | NOS2NOS1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3569290 | 0.71 | NOS2 (0.57) | NOS2NOS1TSHRNPC1HSD17B10 | |
| SCHEMBL3560293 | 0.71 | NOS2 (0.48) | NOS2NOS1 | |
| Hydrochloric Acid SCHEMBL3563512 | 0.70 | NOS2 (0.48) | NOS2NOS1 | |
| SCHEMBL3563611 | 0.70 | NOS2 (1.00) | NOS2NOS1 | |
| SCHEMBL3566770 | 0.69 | ADRB2 (0.32) | PDE5A | |
| SCHEMBL3559005 | 0.69 | NOS2 (0.38) | NOS2NOS1TSHRNPC1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825256-B2 | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20060116515-A1 | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS, INC. | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116515-A1 | Inducible nitric oxide synthase dimerization inhibitors | NOS3, NOS2, NOS1 | NOS2 2/4885NOS1 3/4885HTR1D 2149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.